irinotecan has been researched along with Medulloblastoma in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Chen, Z; Tian, F | 1 |
| Benkimoun, I; Chabi, S; Druillennec, S; Eberhart, CG; Findlay, TH; Fujii, Y; Gabdulkhaev, R; Hawkins, E; Imai, C; Imamura, M; Kakita, A; Malebranche, K; Miyahara, H; Miyashita, S; Murai, J; Nakano, T; Nakata, S; Natsumeda, M; Nobusawa, S; Oishi, M; Okada, M; On, J; Osuka, S; Parthasarathy, A; Pommier, Y; Pouponnot, C; Raabe, EH; Rodriguez, FJ; Saito, T; Sasaki, AT; Takahashi, H; Takeshima, H; Tateishi, K; Tsukamoto, Y; Varlet, P; Watanabe, J; Yamada, S; Yamamoto, T; Yamashita, S; Yoshimura, J | 1 |
| Cole, KA; Fox, E; Ijaz, H; Liu, X; Maris, JM; Minard, CG; Reid, JM; Santi, M; Surrey, LF; Voss, S; Weigel, BJ | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY | 1 |
| Aerts, I; Bailey, S; Breazna, A; Cañete, A; Cisar, L; de Toledo Codina, JS; Dorman, A; Estlin, E; Geoerger, B; Gesner, L; Grill, J; Grundy, RG; Hargrave, D; Leblond, P; Madero, L; Nicolin, G; Perek, D; Verlooy, J | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Battiste, JD; Bonney, PA; Maurer, AJ; McNall-Knapp, RY; Santucci, JA; Sughrue, ME | 1 |
| Aguilera, DG; Fangusaro, J; Goldman, S | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Choi, SA; Jin, X; Kim, H; Kim, SK; Kim, SU; Lee, DH; Lee, HJ; Lee, JY; Lim, I; Lim, SH; Phi, JH; Song, JH; Song, SH; Wang, KC | 1 |
| Aboody, KS; Abramyants, Y; Annala, AJ; Barish, ME; Blanchard, MS; D'Apuzzo, M; Gutova, M; Herrmann, KA; Khankaldyyan, V; Kim, SU; Mittelholtz, K; Moats, RA; Najbauer, J; Shackleford, GM; Shi, XH; Synold, TW | 1 |
| Bucci, F; Cusano, G; Di Francesco, AM; Meco, D; Patriarca, V; Pierri, F; Pisano, C; Riccardi, R; Torella, AR | 1 |
| Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY | 1 |
| Adamson, PC; Bernstein, M; Blaney, SM; Bomgaars, LR; Chen, Z; Das, S; Kadota, R; Krailo, M | 1 |
| Bissery, MC; Boland, I; Gouyette, A; Kalifa, C; Lellouch-Tubiana, A; Morizet, J; Sainte-Rose, C; Santos, A; Terrier-Lacombe, MJ; Vassal, G | 1 |
| Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M | 1 |
6 trial(s) available for irinotecan and Medulloblastoma
| Article | Year |
|---|---|
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cerebellar Neoplasms; Child; Cost-Benefit Analysis; Humans; Irinotecan; Medulloblastoma; Temozolomide | 2022 |
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cerebellar Neoplasms; Child; Humans; Irinotecan; Medulloblastoma; Neuroblastoma; Protein-Tyrosine Kinases; Rhabdomyosarcoma | 2023 |
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Irinotecan; Male; Medulloblastoma; Temozolomide | 2013 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatoblastoma; Humans; Infant; Irinotecan; Male; Medulloblastoma; Neoplasms; Treatment Outcome | 2007 |
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors | 2002 |
12 other study(ies) available for irinotecan and Medulloblastoma
| Article | Year |
|---|---|
Epigenetic upregulation of Schlafen11 renders
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
Topics: Cerebellar Neoplasms; Cisplatin; Epigenesis, Genetic; Hedgehog Proteins; Humans; Irinotecan; Medulloblastoma; Nuclear Proteins; Up-Regulation | 2023 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Radiotherapy; Retrospective Studies; Salvage Therapy; Vincristine; Young Adult | 2013 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Irinotecan; Medulloblastoma; Temozolomide; Young Adult | 2016 |
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Treatment Outcome | 2011 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase.
Topics: Animals; Camptothecin; Carboxylesterase; Cerebellar Neoplasms; Genetic Therapy; Humans; Irinotecan; Male; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neural Stem Cells; Prognosis; Rabbits; Random Allocation; Xenograft Model Antitumor Assays | 2011 |
Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cerebellar Neoplasms; Gene Transfer Techniques; Genetic Therapy; Humans; Irinotecan; Medulloblastoma; Mice; Mice, Nude; Mice, Transgenic; Neural Stem Cells; Prodrugs; Stem Cell Transplantation; Treatment Outcome | 2013 |
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cerebellar Neoplasms; Child; Comet Assay; DNA Damage; Drug Synergism; Humans; Irinotecan; Medulloblastoma; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Platinum Compounds; Xenograft Model Antitumor Assays | 2012 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Medulloblastoma; Recurrence; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Medulloblastoma; Mice; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1997 |